

16th September 2026

Eastbourne District General Hospital

Kings Drive
Eastbourne
East Sussex
BN21 2UD

Tel: 0300 131 4500
Website: www.esht.nhs.uk

Further to your recent request for information made under the Freedom of Information Act (FOIA) 2000, I now set out our answers to your specific questions, and any clarifications sought and provided, as follows:

I am analysing the usage of intra-vitreous injections or implants by the NHS. I would greatly appreciate if you could answer the following questions:

1) How many of the following intra-vitreous injections/implants has your trust administered in the four-month period from May to August 2026:

• Afibercept – Eylea only (Any strength: 2mg or 8mg)	1196
• Afibercept – Eylea 8mg only (21mg/184microlitres solution or 30.1mg/263microlitres solution)	1196
• Afibercept - Biosimilar (any brand other than Eylea)	1440
• Bevacizumab	0
• Dexamethasone	51
• Faricimab	2307
• Fluocinolone acetonide	0
• Ranibizumab - including all Biosimilars	47

***If Eylea cannot be split by 2mg or 8mg strength, please provide the total number of injections/implants of Eylea**

2) Please provide the number of injections/implants by eye condition for the four-month period from May to August 2026:

Please note, if a patient has received multiple injection/implants in the time period specified of May to August 2026, please count the total number of injections/implants that the Trust has administered. I.e. if a patient has received two injections/implants please count that as two.

- Afibercept – Eylea only (Any strength: 2mg or 8mg)
- Afibercept – Eylea 8mg only (21mg/184microlitres solution or 30.1mg/263microlitres solution)
- Afibercept - Biosimilar (any brand other than Eylea)
- Bevacizumab
- Dexamethasone

- Faricimab
- Fluocinolone acetonide
- Ranibizumab - including all Biosimilars

***If Eylea cannot be split by 2mg or 8mg strength, please provide the total number of injections/implants of Eylea used for each indication.**

Treatment	Eye Condition			
	Wet Age-Related Macular Degeneration	Diabetic Macular Oedema (DMO)	Retinal Vein Occlusion (RVO)	Non-infectious Uveitis (NIU)
Aflibercept – Eylea only (Any strength: 2mg or 8mg)	1126	69	0	n/a
Aflibercept – Eylea 8mg only (21mg/184microlitres solution or 30.1mg/263microlitres solution)	1126	69	0	n/a
Aflibercept - Biosimilar (any brand other than Eylea)	749	177	489	n/a
Bevacizumab	0	0	0	n/a
Dexamethasone	0	20	24	0
Faricimab	1892	225	183	n/a
Fluocinolone acetonide	0	0	0	
Ranibizumab - including all Biosimilars	41	0	5	n/a

I trust this information is helpful in its detail or explanation however, if you are dissatisfied with the response, then you have the right to request an internal review. If you wish to seek an internal review, please write to the Freedom of Information Team at esh-tr.foi@nhs.net quoting the above FOI reference number, within 40 working days. Please note the Trust is not obliged to accept a request for an internal review after this time period.

Yours faithfully

Freedom of Information (FOI) Team
 East Sussex Healthcare NHS Trust
 0300 131 4716
 Core Hours of Business: Monday to Friday 9.00am to 4.00pm